<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2017-09-22" updated="2020-01-02">
  <drugbank-id primary="true">DB13913</drugbank-id>
  <name>Belladonna</name>
  <description>Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain [DB00424], [DB00747], and mostly, [DB00572]. These alkaloids are naturally-occurring muscarinic antagonists. [DB00572] is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes. Belladonna is a poisonous plant and belladonna intoxication from accidental ingestion may result in a severe anticholinergic syndrome, which is associated with both central and peripheral manifestations [A32494].</description>
  <cas-number/>
  <unii>WQZ3G9PF0H</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32494</ref-id>
        <pubmed-id>22655106</pubmed-id>
        <citation>Berdai MA, Labib S, Chetouani K, Harandou M: Atropa belladonna intoxication: a case report. Pan Afr Med J. 2012;11:72. Epub 2012 Apr 17.</citation>
      </article>
      <article>
        <ref-id>A32497</ref-id>
        <pubmed-id>27366377</pubmed-id>
        <citation>Demirhan A, Tekelioglu UY, Yildiz I, Korkmaz T, Bilgi M, Akkaya A, Kocoglu H: Anticholinergic Toxic Syndrome Caused by Atropa Belladonna Fruit (Deadly Nightshade): A Case Report. Turk J Anaesthesiol Reanim. 2013 Dec;41(6):226-8. doi: 10.5152/TJAR.2013.43. Epub 2013 May 23.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T28</ref-id>
        <isbn>978-0-7020-3471-8</isbn>
        <citation>13. (2012). In Rang and Dale's Pharmacology  (7th ed., pp. 159-161). Edinburgh: Elsevier/Churchill Livingstone.</citation>
      </textbook>
    </textbooks>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>No therapeutic indications. </indication>
  <pharmacodynamics>The active components of belladonna mediate anticholinergic actions. The main effects include inhibition of secretions such as dry mouth, tachycardia, pupillary dilation and paralysis of accommodation, relaxation of smooth muscles in the gut, bronchi, biliary tract and bladder (urinary retention), and inhibition of gastric acid secretion [T28]. Atropine is a stimulant of the central nervous system [T28]. </pharmacodynamics>
  <mechanism-of-action>The active components of belladonna act as competitive antagonists at muscarinic receptors and block the binding of acetylcholine to the central nervous system and parasympathetic postganglionic muscarinic receptors [A32494].</mechanism-of-action>
  <toxicity>Oral LD50 of atropine is 75 mg/kg in mouse. Clinical manifestations of anticholinergic syndrome include both central and peripheral effects. Central symptoms, which are dose-dependent and anticholinergic agent-specific, include ataxia, disorientation, short-term memory loss, confusion, hallucinations, psychosis, agitated delirium, seizures, coma, respiratory failure or cardiovascular collapse [A32494]. Peripheral effects include mydriasis with cycloplegia, dry mucous membranes, hyperreflexia, flushed skin, diminished bowel sounds or ileus, urinary retention, tachycardia, and hypertension or hypotension [A32494]. Management of anticholinergic intoxication should be symptomatic including gastrointestinal decontamination with activated charcoal [A32494]. The antidote for belladonna poisoning is [DB00981], which is the same as for atropine [A32494]. Physosigmine crosses the blood-brain barrier and reversibly inhibits anticholinesterase. Benzodiazepines are frequently used for sedation to control anticholinergic effects including delirium and agitation [A32497].</toxicity>
  <metabolism>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</metabolism>
  <absorption>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</absorption>
  <half-life>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</half-life>
  <protein-binding>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</protein-binding>
  <route-of-elimination>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</route-of-elimination>
  <volume-of-distribution>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</volume-of-distribution>
  <clearance>For pharmacokinetic information of the active ingredients, refer to [DB00572], [DB00424], or [DB00747].</clearance>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="">Atropa belladona</synonym>
    <synonym language="english" coder="">Atropa belladonna</synonym>
    <synonym language="english" coder="">Deadly nightshade</synonym>
  </synonyms>
  <products>
    <product>
      <name>Belladone Tct</name>
      <labeller>Laboratoire Atlas Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00050105</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>2006-06-14</ended-marketing-on>
      <dosage-form>Tincture</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Belladonna and Opium</name>
      <labeller>Paddock Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0574-7040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-04-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Belladonna and Opium</name>
      <labeller>Paddock Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0574-7045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bellergal Spacetabs</name>
      <labeller>Paladin Labs Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176141</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-01-01</started-marketing-on>
      <ended-marketing-on>2018-06-05</ended-marketing-on>
      <dosage-form>Tablet, extended release</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bellergal Tab</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176133</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cafergot Pb Sup</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176214</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1958-12-31</started-marketing-on>
      <ended-marketing-on>2003-01-15</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cafergot Pb Tab</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00176222</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1951-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-04</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hemorro-dol Sup</name>
      <labeller>Produits Francais Labs Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00540919</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-05-30</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Opium and Belladonna Sup</name>
      <labeller>Smithkline Beecham Pharma Division Of Smithkline Beecham Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01923463</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-07-28</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-opium and Belladona Sup</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00815349</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on>2016-10-28</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Robol Tab</name>
      <labeller>Labs Anglo French</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00474436</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-05</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Opium &amp; Belladonna</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01901869</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wigraine Suppositories</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00489212</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-18</ended-marketing-on>
      <dosage-form>Suppository</dosage-form>
      <strength/>
      <route>Rectal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Wigraine Tab</name>
      <labeller>Organon Canada Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00489220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1980-12-31</started-marketing-on>
      <ended-marketing-on>1999-08-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Belladonna and Opium</name>
      <ingredients>Belladonna + Opium</ingredients>
    </mixture>
    <mixture>
      <name>Belladonna and Opium</name>
      <ingredients>Belladonna + Opium</ingredients>
    </mixture>
    <mixture>
      <name>Opium and Belladonna Sup</name>
      <ingredients>Belladonna + Opium</ingredients>
    </mixture>
    <mixture>
      <name>Bellergal Tab</name>
      <ingredients>Belladonna + Ergotamine + Phenobarbital</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot Pb Tab</name>
      <ingredients>Belladonna + Caffeine + Ergotamine + Pentobarbital</ingredients>
    </mixture>
    <mixture>
      <name>Robol Tab</name>
      <ingredients>Alloin + Belladonna + Ipecac + Phenolphthalein</ingredients>
    </mixture>
    <mixture>
      <name>Wigraine Tab</name>
      <ingredients>Belladonna + Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Wigraine Suppositories</name>
      <ingredients>Belladonna + Caffeine + Ergotamine</ingredients>
    </mixture>
    <mixture>
      <name>Cafergot Pb Sup</name>
      <ingredients>Belladonna + Caffeine + Ergotamine + Pentobarbital</ingredients>
    </mixture>
    <mixture>
      <name>Belladone Tct</name>
      <ingredients>Belladonna</ingredients>
    </mixture>
    <mixture>
      <name>Bellergal Spacetabs</name>
      <ingredients>Belladonna + Ergotamine + Phenobarbital</ingredients>
    </mixture>
    <mixture>
      <name>PMS-opium and Belladona Sup</name>
      <ingredients>Belladonna + Opium</ingredients>
    </mixture>
    <mixture>
      <name>Hemorro-dol Sup</name>
      <ingredients>Balsam of Peru + Belladonna + Benzocaine + Bismuth subcarbonate + Bismuth subnitrate + Boric acid + Ephedrine + Zinc oxide</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Opium &amp; Belladonna</name>
      <ingredients>Belladonna + Opium</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antimuscarinics Antispasmodics</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Tincture</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Suppository</form>
      <route>Rectal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet, extended release</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>12:08.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>672</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Belladonna</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>